E
XORTX Therapeutics Inc. XRTX.V
TSX
Recommendation
Prev Close
$1.55
Volume
--
Avg Vol (90D)
6,229
Market Cap
$4.25M
Dividend & Yield
--
52-Week Range
$1.15 - $4.26
P/E (TTM)
--
EPS (TTM)
-$1.35
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge
4/18/2025 - GuruFocus
XORTX Therapeutics receives Nasdaq notice for non-compliance
4/18/2025 - SeekingAlpha.com: All News
XORTX Therapeutics receives Nasdaq notice for non-compliance
4/18/2025 - Seeking Alpha - Healthcare
XORTX Therapeutics (XRTX) Notified of Nasdaq Minimum Bid Price Non-Compliance XRTX Stock News
4/18/2025 - GuruFocus
XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency
4/18/2025 - TipRanks Financial Blog
Xortx Therapeutics discloses Nasdaq notification regarding minimum bid price
4/17/2025 - The Fly
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
4/17/2025 - Globe Newswire
XORTX Therapeutics Releases Annual Information Form for 2024
4/1/2025 - TipRanks Financial Blog
Xortx Therapeutics to provide Type B meeting package to FDA during next week
3/19/2025 - The Fly
XORTX Announces Update for Discussion with the FDA
3/19/2025 - Globe Newswire
Xortx Therapeutics commences gout program NDA discussions with FDA
2/24/2025 - The Fly
XORTX Commences Gout Program NDA Discussions with the FDA
2/24/2025 - Globe Newswire
ARMISTICE CAPITAL, LLC Acquires Shares in XORTX Therapeutics Inc
2/15/2025 - GuruFocus
XORTX to Present at Microcap Conference
1/29/2025 - Globe Newswire
XORTX Therapeutics Announces Auditor Transition
1/17/2025 - TipRanks Financial Blog
XORTX Announces Change of Auditor
1/17/2025 - Globe Newswire
XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program
1/6/2025 - TipRanks Financial Blog
Xortx Therapeutics announces launch of late stage program to treat gout
1/6/2025 - The Fly
XORTX Adds Late Stage Gout Program to Pipeline
1/6/2025 - Globe Newswire
XORTX Therapeutics Welcomes New CFO Dr. Bumby
12/19/2024 - TipRanks Financial Blog
Xortx Therapeutics appoints Bumby as Chief Financial Officer
12/19/2024 - The Fly
XORTX Strengthens Executive Team
12/19/2024 - Globe Newswire
Xortx Therapeutics announces presentation at Rare, Genetic Disease Summit
12/12/2024 - The Fly
XORTX Announces Presentation at the Rare and Genetic Disease Summit
12/12/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$2.90M
EBIT (TTM)
-$2.62M
Net Income (TTM)
-$3.31M
Balance Sheet
Total Assets (Q)
$4.09M
Total Debt (Q)
$38.80K
Total Liabilities (Q)
$758.00K
Book Value Per Share (Q)
$1.98
Cash Flow
Cash from Operations (TTM)
-$3.68M
Cash from Investing (TTM)
-$38.90K
Cash from Financing (TTM)
$2.78M
Net Change in Cash (TTM)
-$974.00K
Filings
Filing Date
Wednesday, March 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.32
7-Day Total Return
-0.78%
30-Day Total Return
-2.29%
60-Day Total Return
-7.25%
90-Day Total Return
-21.95%
Year to Date Total Return
-22.89%
1-Year Total Return
-67.59%
2-Year Total Return
-84.71%
3-Year Total Return
-93.54%
5-Year Total Return
-93.45%
52-week Low
Apr 11, 2025 - $1.15
52-week High
Apr 29, 2024 - $4.26
Valuation
Market Cap
$4.25M - Nano Cap
Enterprise Value
$1.71M
Price/Sales (TTM)
--
Price/Book (Q)
0.78
Dividends and Shares
Shares Outstanding
3.28M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.xortx.com
Phone Number
403-455-7727
Address
3710 – 33rd Street NW
Calgary, AB T2L 2M1
Country
Canada
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug... more